Synoxa Sciences Inc, spun out of NC State University, develops small molecule antibiotics that are effective against multidrug-resistant (MDR) bacterial infections, which is one of the top-three threats to humanity according to the World Health Organization. The firm's small molecules have efficacy against a variety of MDR bacterial pathogens and has potential applications for orthopedic infections, endocarditis, burn wound infections, and gram negative pathogens.
